On Friday, Krystal Biotech got an upgrade for its IBD SmartSelect Composite Rating from 93 to 97.
The revised score means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength.
Krystal Biotech is not currently near a proper buy point. Look for the stock to form and break out of a new base.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock sports an 82 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth tops 82% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
The company reported a 407% rise in earnings for Q4. Revenue growth fell to 116%, down from 879% in the prior quarter.
Krystal Biotech earns the No. 6 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
